Global Immuno Oncology Assays Market
Global Immuno Oncology Assays Market

Immuno Oncology Assays Comprehensive Study by Application (Research Applications, Clinical Diagnostics), Indication (Lung Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Other Cancers), Technology (Immunoassay, PCR, NGS, Flow Cytometry, Other Technologies), Product type (Consumables, Software), Therapy (Monoclonal antibodies (mAb), Checkpoint inhibitor therapy, Cytokines, Vaccine therapy, Adoptive cell transfer)

Immuno Oncology Assays Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Mar 2021 Edition 226 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Immuno Oncology Assays Market?

Over the past decade, immuno-oncology (IO) has appeared as a novel and powerful approach to cancer treatment through the stimulation of the bodyís own immune system to kill cancer cells. This newly approved method of treating cancer is rapidly developing, with many accelerated permissions by the US Food and Drug Administration and European Medicines Agency in 2019. Immuno-oncology is an area of scientific research included in investigating how the immune system can fight cancers. It is a method used to find out the potential of the immune system to fight against cancer cells. Further, cancer has become one of the most frequent causes of mortality in western industrialized countries. Immune oncological approaches are serving to determine new potent curative cancer treatment that could possibly even lead to the eradication of most types of cancer.

The market study is being classified, by Application (Research Applications and Clinical Diagnostics) and major geographies with country level break-up.

Thermo Fischer Scientific (United States), Roche Diagnostics (Switzerland), Agilent Technologies (United States), Illumina (United States), F. Hoffmann-La Roche Ltd (Switzerland), HTG Molecular Diagnostics, Inc. (United States), Illumina, Inc.(United States), Merck KGaA (United State), PerkinElmer Inc. (United States) and Qiagen (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Sartorius AG (Germany) and NanoString Technologies, Inc. (United States).

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Immuno Oncology Assays market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Immuno Oncology Assays market by Type, Application and Region.

On the basis of geography, the market of Immuno Oncology Assays has been segmented into . Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rise in cancer incidence across the globe and increase in R&D activities for the developing cancer treatment
  • Rising Incidence of Cancer and Increasing Adoption of Targeted Therapy
  • A cancer diagnosis is increasing the need for the reagent and antibodies increases, thus propelling the segment growth.

Market Trend
  • Increased focus on developing automated immuno-oncology assay is anticipated to create lucrative opportunities in the near future.

Restraints
  • Unfavourable Regulatory and Reimbursement Scenario

Opportunities
  • Increasing use of Immuno Oncology Assays in cancer treatment as Immunotherapy is used to fight off diseases such as cancer by stimulating or boosting the patients own immune system or giving man-made immune system proteins to attack cancer cells.

Challenges
  • High Amount of Capital Investments and Low Benefit-Cost Ratio


In March 2020 Gilad acquired an immune-oncology company for USD 4.9Billion. The acquisition will give Gilead access to Forty-Sevenís investigational lead product candidate, magrolimab, a monoclonal antibody in clinical development for the treatment of numerous cancers, including myelodysplastic syndrome, acute myeloid leukaemia, and diffuse large B-cell lymphoma, the press release said.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Immuno Oncology Assays Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Research Applications
  • Clinical Diagnostics
By Indication
  • Lung Cancer
  • Colorectal Cancer
  • Melanoma
  • Bladder Cancer
  • Other Cancers

By Technology
  • Immunoassay
  • PCR
  • NGS
  • Flow Cytometry
  • Other Technologies

By Product type
  • Consumables
  • Software

By Therapy
  • Monoclonal antibodies (mAb)
  • Checkpoint inhibitor therapy
  • Cytokines
  • Vaccine therapy
  • Adoptive cell transfer

By Regions
    • 1. Market Overview
      • 1.1. Introduction
      • 1.2. Scope/Objective of the Study
        • 1.2.1. Research Objective
    • 2. Executive Summary
      • 2.1. Introduction
    • 3. Market Dynamics
      • 3.1. Introduction
      • 3.2. Market Drivers
        • 3.2.1. Rise in cancer incidence across the globe and increase in R&D activities for the developing cancer treatment
        • 3.2.2. Rising Incidence of Cancer and Increasing Adoption of Targeted Therapy
        • 3.2.3. A cancer diagnosis is increasing the need for the reagent and antibodies increases, thus propelling the segment growth.
      • 3.3. Market Challenges
        • 3.3.1. High Amount of Capital Investments and Low Benefit-Cost Ratio
      • 3.4. Market Trends
        • 3.4.1. Increased focus on developing automated immuno-oncology assay is anticipated to create lucrative opportunities in the near future.
    • 4. Market Factor Analysis
      • 4.1. Porters Five Forces
      • 4.2. Supply/Value Chain
      • 4.3. PESTEL analysis
      • 4.4. Market Entropy
      • 4.5. Patent/Trademark Analysis
    • 5. Global Immuno Oncology Assays, by Application, Indication, Technology, Product type and Therapy (value) (2015-2020)
      • 5.1. Introduction
      • 5.2. Global Immuno Oncology Assays (Value)
        • 5.2.1. Global Immuno Oncology Assays by: Application (Value)
          • 5.2.1.1. Research Applications
          • 5.2.1.2. Clinical Diagnostics
        • 5.2.2. Global Immuno Oncology Assays by: Indication (Value)
          • 5.2.2.1. Lung Cancer
          • 5.2.2.2. Colorectal Cancer
          • 5.2.2.3. Melanoma
          • 5.2.2.4. Bladder Cancer
          • 5.2.2.5. Other Cancers
        • 5.2.3. Global Immuno Oncology Assays by: Technology (Value)
          • 5.2.3.1. Immunoassay
          • 5.2.3.2. PCR
          • 5.2.3.3. NGS
          • 5.2.3.4. Flow Cytometry
          • 5.2.3.5. Other Technologies
        • 5.2.4. Global Immuno Oncology Assays by: Product type (Value)
          • 5.2.4.1. Consumables
          • 5.2.4.2. Software
    • 6. Immuno Oncology Assays: Manufacturers/Players Analysis
      • 6.1. Competitive Landscape
        • 6.1.1. Market Share Analysis
          • 6.1.1.1. Top 3
          • 6.1.1.2. Top 5
      • 6.2. Peer Group Analysis (2020)
      • 6.3. BCG Matrix
      • 6.4. Company Profile
        • 6.4.1. Thermo Fischer Scientific (United States)
          • 6.4.1.1. Business Overview
          • 6.4.1.2. Products/Services Offerings
          • 6.4.1.3. Financial Analysis
          • 6.4.1.4. SWOT Analysis
        • 6.4.2. Roche Diagnostics (Switzerland)
          • 6.4.2.1. Business Overview
          • 6.4.2.2. Products/Services Offerings
          • 6.4.2.3. Financial Analysis
          • 6.4.2.4. SWOT Analysis
        • 6.4.3. Agilent Technologies (United States)
          • 6.4.3.1. Business Overview
          • 6.4.3.2. Products/Services Offerings
          • 6.4.3.3. Financial Analysis
          • 6.4.3.4. SWOT Analysis
        • 6.4.4. Illumina (United States)
          • 6.4.4.1. Business Overview
          • 6.4.4.2. Products/Services Offerings
          • 6.4.4.3. Financial Analysis
          • 6.4.4.4. SWOT Analysis
        • 6.4.5. F. Hoffmann-La Roche Ltd (Switzerland)
          • 6.4.5.1. Business Overview
          • 6.4.5.2. Products/Services Offerings
          • 6.4.5.3. Financial Analysis
          • 6.4.5.4. SWOT Analysis
        • 6.4.6. HTG Molecular Diagnostics, Inc. (United States)
          • 6.4.6.1. Business Overview
          • 6.4.6.2. Products/Services Offerings
          • 6.4.6.3. Financial Analysis
          • 6.4.6.4. SWOT Analysis
        • 6.4.7. Illumina, Inc.(United States)
          • 6.4.7.1. Business Overview
          • 6.4.7.2. Products/Services Offerings
          • 6.4.7.3. Financial Analysis
          • 6.4.7.4. SWOT Analysis
        • 6.4.8. Merck KGaA (United State)
          • 6.4.8.1. Business Overview
          • 6.4.8.2. Products/Services Offerings
          • 6.4.8.3. Financial Analysis
          • 6.4.8.4. SWOT Analysis
        • 6.4.9. PerkinElmer Inc. (United States)
          • 6.4.9.1. Business Overview
          • 6.4.9.2. Products/Services Offerings
          • 6.4.9.3. Financial Analysis
          • 6.4.9.4. SWOT Analysis
        • 6.4.10. Qiagen (United States)
          • 6.4.10.1. Business Overview
          • 6.4.10.2. Products/Services Offerings
          • 6.4.10.3. Financial Analysis
          • 6.4.10.4. SWOT Analysis
    • 7. Global Immuno Oncology Assays Sale, by Application, Indication, Technology, Product type and Therapy (value) (2021-2026)
      • 7.1. Introduction
      • 7.2. Global Immuno Oncology Assays (Value)
        • 7.2.1. Global Immuno Oncology Assays by: Application (Value)
          • 7.2.1.1. Research Applications
          • 7.2.1.2. Clinical Diagnostics
        • 7.2.2. Global Immuno Oncology Assays by: Indication (Value)
          • 7.2.2.1. Lung Cancer
          • 7.2.2.2. Colorectal Cancer
          • 7.2.2.3. Melanoma
          • 7.2.2.4. Bladder Cancer
          • 7.2.2.5. Other Cancers
        • 7.2.3. Global Immuno Oncology Assays by: Technology (Value)
          • 7.2.3.1. Immunoassay
          • 7.2.3.2. PCR
          • 7.2.3.3. NGS
          • 7.2.3.4. Flow Cytometry
          • 7.2.3.5. Other Technologies
        • 7.2.4. Global Immuno Oncology Assays by: Product type (Value)
          • 7.2.4.1. Consumables
          • 7.2.4.2. Software
    • 8. Appendix
      • 8.1. Acronyms
    • 9. Methodology and Data Source
      • 9.1. Methodology/Research Approach
        • 9.1.1. Research Programs/Design
        • 9.1.2. Market Size Estimation
        • 9.1.3. Market Breakdown and Data Triangulation
      • 9.2. Data Source
        • 9.2.1. Secondary Sources
        • 9.2.2. Primary Sources
      • 9.3. Disclaimer
    List of Tables
    • Table 1. Immuno Oncology Assays: by Application(USD Million)
    • Table 2. Immuno Oncology Assays: by Indication(USD Million)
    • Table 3. Immuno Oncology Assays: by Technology(USD Million)
    • Table 4. Immuno Oncology Assays: by Product type(USD Million)
    • Table 5. Company Basic Information, Sales Area and Its Competitors
    • Table 6. Company Basic Information, Sales Area and Its Competitors
    • Table 7. Company Basic Information, Sales Area and Its Competitors
    • Table 8. Company Basic Information, Sales Area and Its Competitors
    • Table 9. Company Basic Information, Sales Area and Its Competitors
    • Table 10. Company Basic Information, Sales Area and Its Competitors
    • Table 11. Company Basic Information, Sales Area and Its Competitors
    • Table 12. Company Basic Information, Sales Area and Its Competitors
    • Table 13. Company Basic Information, Sales Area and Its Competitors
    • Table 14. Company Basic Information, Sales Area and Its Competitors
    • Table 15. Immuno Oncology Assays: by Application(USD Million)
    • Table 16. Immuno Oncology Assays: by Indication(USD Million)
    • Table 17. Immuno Oncology Assays: by Technology(USD Million)
    • Table 18. Immuno Oncology Assays: by Product type(USD Million)
    • Table 19. Research Programs/Design for This Report
    • Table 20. Key Data Information from Secondary Sources
    • Table 21. Key Data Information from Primary Sources
    List of Figures
    • Figure 1. Porters Five Forces
    • Figure 2. Supply/Value Chain
    • Figure 3. PESTEL analysis
    • Figure 4. Global Immuno Oncology Assays: by Application USD Million (2015-2020)
    • Figure 5. Global Immuno Oncology Assays: by Indication USD Million (2015-2020)
    • Figure 6. Global Immuno Oncology Assays: by Technology USD Million (2015-2020)
    • Figure 7. Global Immuno Oncology Assays: by Product type USD Million (2015-2020)
    • Figure 8. Global Immuno Oncology Assays share by Players 2020 (%)
    • Figure 9. Global Immuno Oncology Assays share by Players (Top 3) 2020(%)
    • Figure 10. Global Immuno Oncology Assays share by Players (Top 5) 2020(%)
    • Figure 11. BCG Matrix for key Companies
    • Figure 12. Thermo Fischer Scientific (United States) Revenue, Net Income and Gross profit
    • Figure 13. Thermo Fischer Scientific (United States) Revenue: by Geography 2020
    • Figure 14. Roche Diagnostics (Switzerland) Revenue, Net Income and Gross profit
    • Figure 15. Roche Diagnostics (Switzerland) Revenue: by Geography 2020
    • Figure 16. Agilent Technologies (United States) Revenue, Net Income and Gross profit
    • Figure 17. Agilent Technologies (United States) Revenue: by Geography 2020
    • Figure 18. Illumina (United States) Revenue, Net Income and Gross profit
    • Figure 19. Illumina (United States) Revenue: by Geography 2020
    • Figure 20. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
    • Figure 21. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2020
    • Figure 22. HTG Molecular Diagnostics, Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 23. HTG Molecular Diagnostics, Inc. (United States) Revenue: by Geography 2020
    • Figure 24. Illumina, Inc.(United States) Revenue, Net Income and Gross profit
    • Figure 25. Illumina, Inc.(United States) Revenue: by Geography 2020
    • Figure 26. Merck KGaA (United State) Revenue, Net Income and Gross profit
    • Figure 27. Merck KGaA (United State) Revenue: by Geography 2020
    • Figure 28. PerkinElmer Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 29. PerkinElmer Inc. (United States) Revenue: by Geography 2020
    • Figure 30. Qiagen (United States) Revenue, Net Income and Gross profit
    • Figure 31. Qiagen (United States) Revenue: by Geography 2020
    • Figure 32. Global Immuno Oncology Assays: by Application USD Million (2021-2026)
    • Figure 33. Global Immuno Oncology Assays: by Indication USD Million (2021-2026)
    • Figure 34. Global Immuno Oncology Assays: by Technology USD Million (2021-2026)
    • Figure 35. Global Immuno Oncology Assays: by Product type USD Million (2021-2026)
    Some of the key companies/manufacturers profiled in the report
    • Thermo Fischer Scientific (United States)
    • Roche Diagnostics (Switzerland)
    • Agilent Technologies (United States)
    • Illumina (United States)
    • F. Hoffmann-La Roche Ltd (Switzerland)
    • HTG Molecular Diagnostics, Inc. (United States)
    • Illumina, Inc.(United States)
    • Merck KGaA (United State)
    • PerkinElmer Inc. (United States)
    • Qiagen (United States)
    Additional players considered in the study are as follows:
    Sartorius AG (Germany) , NanoString Technologies, Inc. (United States)
    Select License Type
    Sample Report Enquiry Before Buy Request Discount

    Speak with Analyst

    Want to find out more about this report?

    Get Free Consultation